575 related articles for article (PubMed ID: 20865644)
1. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.
Köse O; Zimmerhackl LB; Jungraithmayr T; Mache C; Nürnberger J
Semin Thromb Hemost; 2010 Sep; 36(6):669-72. PubMed ID: 20865644
[TBL] [Abstract][Full Text] [Related]
2. Eculizumab for atypical hemolytic-uremic syndrome.
Nürnberger J; Philipp T; Witzke O; Opazo Saez A; Vester U; Baba HA; Kribben A; Zimmerhackl LB; Janecke AR; Nagel M; Kirschfink M
N Engl J Med; 2009 Jan; 360(5):542-4. PubMed ID: 19179328
[No Abstract] [Full Text] [Related]
3. Autoantibodies in haemolytic uraemic syndrome (HUS).
Skerka C; Józsi M; Zipfel PF; Dragon-Durey MA; Fremeaux-Bacchi V
Thromb Haemost; 2009 Feb; 101(2):227-32. PubMed ID: 19190803
[TBL] [Abstract][Full Text] [Related]
4. Complement activation in diseases presenting with thrombotic microangiopathy.
Meri S
Eur J Intern Med; 2013 Sep; 24(6):496-502. PubMed ID: 23743117
[TBL] [Abstract][Full Text] [Related]
5. A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome.
Westra D; Wetzels JF; Volokhina EB; van den Heuvel LP; van de Kar NC
Neth J Med; 2012 Apr; 70(3):121-9. PubMed ID: 22516576
[TBL] [Abstract][Full Text] [Related]
6. Posttransplant recurrence of atypical hemolytic uremic syndrome.
Valoti E; Alberti M; Noris M
J Nephrol; 2012; 25(6):911-7. PubMed ID: 22760880
[TBL] [Abstract][Full Text] [Related]
7. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy.
Fakhouri F; Frémeaux-Bacchi V; Loirat C
Eur J Intern Med; 2013 Sep; 24(6):492-5. PubMed ID: 23756030
[TBL] [Abstract][Full Text] [Related]
8. Anti-factor H autoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS.
Dragon-Durey MA; Blanc C; Garnier A; Hofer J; Sethi SK; Zimmerhackl LB
Semin Thromb Hemost; 2010 Sep; 36(6):633-40. PubMed ID: 20865640
[TBL] [Abstract][Full Text] [Related]
9. The role of defective complement control in hemolytic uremic syndrome.
Zipfel PF; Misselwitz J; Licht C; Skerka C
Semin Thromb Hemost; 2006 Mar; 32(2):146-54. PubMed ID: 16575689
[TBL] [Abstract][Full Text] [Related]
10. Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.
Diamante Chiodini B; Davin JC; Corazza F; Khaldi K; Dahan K; Ismaili K; Adams B
Pediatrics; 2014 Jun; 133(6):e1764-8. PubMed ID: 24843055
[TBL] [Abstract][Full Text] [Related]
11. Atypical hemolytic uremic syndrome due to factor H autoantibody.
Uslu-Gökceoğlu A; Doğan CS; Comak E; Koyun M; Akman S
Turk J Pediatr; 2013; 55(1):86-9. PubMed ID: 23692839
[TBL] [Abstract][Full Text] [Related]
12. Interaction of Shiga toxin 2 with complement regulators of the factor H protein family.
Poolpol K; Orth-Höller D; Speth C; Zipfel PF; Skerka C; de Córdoba SR; Brockmeyer J; Bielaszewska M; Würzner R
Mol Immunol; 2014 Mar; 58(1):77-84. PubMed ID: 24317278
[TBL] [Abstract][Full Text] [Related]
13. Atypical hemolytic uremic syndrome: update on the complement system and what is new.
Hirt-Minkowski P; Dickenmann M; Schifferli JA
Nephron Clin Pract; 2010; 114(4):c219-35. PubMed ID: 20090363
[TBL] [Abstract][Full Text] [Related]
14. Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome.
Walsh PR; Johnson S
Pediatr Nephrol; 2019 Sep; 34(9):1485-1492. PubMed ID: 30058046
[TBL] [Abstract][Full Text] [Related]
15. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.
Xie L; Nester CM; Reed AI; Zhang Y; Smith RJ; Thomas CP
Transplant Proc; 2012 Dec; 44(10):3037-40. PubMed ID: 23195022
[TBL] [Abstract][Full Text] [Related]
16. Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment.
Raina R; Krishnappa V; Blaha T; Kann T; Hein W; Burke L; Bagga A
Ther Apher Dial; 2019 Feb; 23(1):4-21. PubMed ID: 30294946
[TBL] [Abstract][Full Text] [Related]
17. Atypical hemolytic uremic syndrome.
Loirat C; Frémeaux-Bacchi V
Orphanet J Rare Dis; 2011 Sep; 6():60. PubMed ID: 21902819
[TBL] [Abstract][Full Text] [Related]
18. The decay accelerating factor mutation I197V found in hemolytic uraemic syndrome does not impair complement regulation.
Kavanagh D; Burgess R; Spitzer D; Richards A; Diaz-Torres ML; Goodship JA; Hourcade DE; Atkinson JP; Goodship TH
Mol Immunol; 2007 May; 44(12):3162-7. PubMed ID: 17368771
[TBL] [Abstract][Full Text] [Related]
19. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation.
Davin JC; Gracchi V; Bouts A; Groothoff J; Strain L; Goodship T
Am J Kidney Dis; 2010 Apr; 55(4):708-11. PubMed ID: 19854549
[TBL] [Abstract][Full Text] [Related]
20. Ockham's razor defeated: about two atypical cases of hemolytic uremic syndrome.
Schwarz C; Brehon A; Mousseaux C; Luque Y; Senet P; Mariani P; Mohamadou I; Zafrani L; Frémeaux-Bacchi V; Rondeau E; Buob D; Rafat C
BMC Nephrol; 2020 Jul; 21(1):269. PubMed ID: 32652955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
